These reductions would be expected to impair normal CME, and this was demonstrated through the use of FM1-43 to be the case in iPSC-derived dopaminergic cultures from LRRK2-R1441C and LRRK2-G2019S PD patients, compared with cells from healthy controls. The gene discussed is LRRK2; the disease is Parkinson disease.